ENOB - Enochian Biosciences shares rise after FDA accepts hepatitis treatment Pre-IND request

Enochian BioSciences (ENOB) shares climb more than 7% during premarket trading after announcing that the U.S. FDA has accepted a Pre-IND (Investigational New Drug) request for a potential cure of hepatitis B virus ((HBV)) infection.The Pre-IND request was made based on promising data from a proof-of-concept study conducted in chimeric mice."We are encouraged by the novel mechanism of action, called Hijack RNA that shows promise as a potential platform technology for coronaviruses (including the cause of COVID-19), influenza and HBV, and are exploring its use against HIV," Mark Dybul, Executive Vice Chairperson of the board of Enochian said.The company's shares have nearly doubled in value YTD.Enochian had acquired an exclusive license for an innovative technology to potentially treat and prevent all variants of coronavirus, including the cause of COVID-19, as well as influenza, in June.

For further details see:

Enochian Biosciences shares rise after FDA accepts hepatitis treatment Pre-IND request